周四盘前，生物技术公司Nurix Therapeutics（NRIX）股价大幅飙升28.60%，引发市场广泛关注。这一显著涨幅主要源于公司最新发布的季度财报远超市场预期。
根据公司公告，截至5月31日的季度财报显示，Nurix Therapeutics调整后每股亏损为0.52美元，明显优于分析师平均预期的0.73美元亏损。更为亮眼的是，公司营收同比大幅增长264.3%，达到4406万美元，远超分析师预期的1701万美元。这份亮眼的业绩报告无疑增强了投资者对公司未来发展前景的信心。
值得注意的是，分析师对Nurix Therapeutics的评级普遍较为积极。在18位分析师中，16位给予"强烈买入"或"买入"评级，2位给予"持有"评级，没有"卖出"或"强烈卖出"评级。这种积极的市场情绪，加上超预期的财报表现，共同推动了公司股价的大幅上涨。尽管公司今年至今的股价表现不佳，但这份优异的财报可能成为公司股价强劲反弹的重要催化剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.